Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Go back to Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers| (NASDAQ: PPCB) | Delayed: 0.28 +0.01 (3.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.27 | 52 Week High | $ | |||
| Open | $0.28 | 52 Week Low | $ | |||
| Day High | $0.28 | P/E | N/A | |||
| Day Low | $0.25 | EPS | $ | |||
| Volume | 202,084 | |||||
| (NASDAQ: PPCB) | Delayed: 0.28 +0.01 (3.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.27 | 52 Week High | $ | |||
| Open | $0.28 | 52 Week Low | $ | |||
| Day High | $0.28 | P/E | N/A | |||
| Day Low | $0.25 | EPS | $ | |||
| Volume | 202,084 | |||||



